Zoetis Inc. logo
Zoetis Inc. (ZTS)
Compare

Zoetis Inc. (ZTS) EPS Diluted: 6.02

Is Zoetis Inc.’s EPS diluted high or low?

Zoetis Inc.'s EPS diluted of 6.02 is 26% above its 5-year average of 4.79, near the high end of its 5-year range (3.42–6.02).

The EPS diluted for Zoetis Inc. (ZTS) is 6.02. It is above its 12-month average by 4.79% (5.74).

ZTS EPS Diluted Chart

ZTS EPS Diluted
6.02+10.05% 1Y
Zoom

ZTS Average EPS Diluted Chart

ZTS Current vs Average EPS Diluted Chart

ZTS EPS Diluted Metrics

EPS DILUTED

6.02

EPS DILUTED AVG TTM

5.74

EPS DILUTED AVG 3Y

5.26

EPS DILUTED AVG 5Y

4.79

EPS DILUTED AVG 10Y

3.53

EPS DILUTED AVG 15Y

2.67

EPS DILUTED AVG 20Y

2.50

CURRENT VS TTM AVG

+4.79%

CURRENT VS 3Y AVG

+14.39%

CURRENT VS 5Y AVG

+25.68%

CURRENT VS 10Y AVG

+70.41%

CURRENT VS 15Y AVG

+125.89%

CURRENT VS 20Y AVG

+141.20%

Zoetis Inc. EPS Diluted Formula & Definition

EPS Diluted includes the effect of convertible securities, options, and other potential shares. Compare it with basic EPS to see the impact of potential dilution.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Zoetis Inc. EPS Diluted FAQ

What is the EPS diluted for Zoetis Inc. (ZTS)?
The EPS diluted for ZTS stock is 6.02.
Is Zoetis Inc.'s EPS diluted high or low?
Zoetis Inc.'s EPS diluted of 6.02 is 26% above its 5-year average of 4.79, near the high end of its 5-year range (3.42–6.02).
What is the TTM average EPS diluted for Zoetis Inc. (ZTS)?
The TTM average EPS diluted for ZTS stock is 5.74.
What is the 3Y average EPS diluted for Zoetis Inc. (ZTS)?
The 3Y average EPS diluted for ZTS stock is 5.26.
What is the 5Y average EPS diluted for Zoetis Inc. (ZTS)?
The 5Y average EPS diluted for ZTS stock is 4.79.
What is the 10Y average EPS diluted for Zoetis Inc. (ZTS)?
The 10Y average EPS diluted for ZTS stock is 3.53.
What is the 15Y average EPS diluted for Zoetis Inc. (ZTS)?
The 15Y average EPS diluted for ZTS stock is 2.67.
What is the 20Y average EPS diluted for Zoetis Inc. (ZTS)?
The 20Y average EPS diluted for ZTS stock is 2.50.

Zoetis Inc. EPS Diluted History

DATEEPS DILUTED
2025-12-316.02
2024-12-315.47
2023-12-315.07
2022-12-314.49
2021-12-314.27
2020-12-313.42
2019-12-313.11
2018-12-312.93
2017-12-311.75
2016-12-311.65
2015-12-310.68
2014-12-311.16
2013-12-311.01
2012-12-310.87
2011-12-310.51
2010-12-310.23
2009-12-31-0.21

About Zoetis Inc.

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Parsippany, NJ
13,800 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Kristin C. Peck